Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00943501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and pharmacodynamics (the determination of the effect over time and the duration of action) of multiple doses of liraglutide in the pediatric population (children).
Study identification
- NCT ID
- NCT00943501
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 10 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Aug 31, 2011
- Completion
- Aug 31, 2011
- Last update posted
- Jan 25, 2017
2009 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Cypress | California | 90630 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90036 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90048-1869 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Iowa City | Iowa | 52242 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40202 | — |
| Novo Nordisk Investigational Site | Kansas City | Missouri | 64108-4619 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45229 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44106 | — |
| Novo Nordisk Investigational Site | Toledo | Ohio | 43606 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15224 | — |
| Novo Nordisk Investigational Site | Memphis | Tennessee | 38103-2800 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00943501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2017 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00943501 live on ClinicalTrials.gov.